Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P+R-ICE in Relapsed/Refractory DLBCL
NCT05221645Phase 2Active, not recruiting
- Sponsor
- University of Southampton
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Southampton. Started Jun 2022; status: active, not recruiting.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05221645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221645.